Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
作者： Sae-Won Han , Tae-You Kim , Pil Gyu Hwang , Soohyun Jeong , Jeongmi Kim
关键词:
摘要: Purpose This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non–small-…
jco.org参考文章(21)
David Solit, Mark M. Moasser, Qing-Bai She, Andrea Basso, Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling Clinical Cancer Research. ,vol. 9, pp. 4340- 4346 ,(2003)
H Cortes-Funes, H Soto Parra, Extensive experience of disease control with gefitinib and the role of prognostic markers. British Journal of Cancer. ,vol. 89, ,(2003) , 10.1038/SJ.BJC.6601476
Roberto Bianco, Incheol Shin, Christoph A Ritter, F Michael Yakes, Andrea Basso, Neal Rosen, Junji Tsurutani, Phillip A Dennis, Gordon B Mills, Carlos L Arteaga, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene. ,vol. 22, pp. 2812- 2822 ,(2003) , 10.1038/SJ.ONC.1206388
F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C. T. Paties, L. Lombardo, C. Calandri, G. Bellezza, M. Tonato, L. Crino, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. ,vol. 96, pp. 1133- 1141 ,(2004) , 10.1093/JNCI/DJH217
Raffaella Sordella, Daphne W Bell, Daniel A Haber, Jeffrey Settleman, Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Science. ,vol. 305, pp. 1163- 1167 ,(2004) , 10.1126/SCIENCE.1101637
N Magné, J L Fischel, A Dubreuil, P Formento, M-F Poupon, P Laurent-Puig, G Milano, Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) British Journal of Cancer. ,vol. 86, pp. 1518- 1523 ,(2002) , 10.1038/SJ.BJC.6600299
John Mendelsohn, Jose Baselga, Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2787- 2799 ,(2003) , 10.1200/JCO.2003.01.504
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Sae-Won Han, Pil Gyu Hwang, Doo Hyun Chung, Dong-Wan Kim, Seock-Ah Im, Young Tae Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim, Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer† International Journal of Cancer. ,vol. 113, pp. 109- 115 ,(2005) , 10.1002/IJC.20550
Renee Bailey, Mark Kris, Michael Wolf, Andrea Kay, Steven Averbuch, Jon Askaa, Mette Janas, Karsten Schmidt, Masahiro Fukuoka, O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)91900-3